Journal article
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, H Iwata, M Campone, R Nanda, R Hui, G Curigliano, D Toppmeyer, J O'Shaughnessy, S Loi, S Paluch-Shimon, AR Tan, D Card, J Zhao, V Karantza Show all
ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2019
Abstract
BACKGROUND: Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC. PATIENTS AND METHODS: Eligible patients had centrally confirmed mTNBC, ≥1 systemic therapy for metastatic disease, prior treatment with anthracycline and taxane in any disease setting, and progression on or after the most recent therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. Primary end points were objective response rate in the total and PD-L1-positive populations, and safety. Secondary end points..
View full abstractGrants
Funding Acknowledgements
This work was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. There are no grants associated with this manuscript.